Ascentage Pharma Stock Could More Than Double: Analyst
William Blair sees major upside for Ascentage Pharma stock as the cancer drug developer approaches three pivotal trial results in 2027.
Stocks · News reference
Takeda Reports TAK-881 Cuts Infusion Volume 50%, Single-Site Infusion Time 42.6% Vs. HyQvia In Phase 2/3 Immunodeficiency Trial
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Reported Earlier, Takeda Launches ORZEYFUL In Japan And China As First-In-Class Orexin Agonist For Narcolepsy Type 1, With US Launch Set For Next Month After DEA Scheduling
− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s
Takeda Presents Phase 3 Data Showing Once-Daily Oral Zasocitinib Delivers Higher PASI 100 At 36.5% Vs 13.9% And PASI 90 At 62.5% Vs 34.0% Than Deucravacitinib At Week 16; Under FDA, EMA Review For Plaque Psoriasis
Head-to-head LATITUDE Atlas data showed zasocitinib demonstrated statistical superiority to deucravacitinib across the primary and all key secondary efficacy endpoints with higher rates of complete skin clearance